Overview

A Study of Efficacy, Safety, and Tolerability of KAN-101 in People With Celiac Disease

Status:
Recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
The study goal is to evaluate the efficacy, safety, and tolerability of KAN-101 in participants with Celiac Disease (CeD)
Phase:
Phase 2
Details
Lead Sponsor:
Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA
Collaborator:
Pfizer